Amgen announces erenumab significantly reduces monthly migraine days
Amgen announced positive top-line results for erenumab (AMG 334) from A Phase 3, RandomIzed, double-blind, placebo-controlled Study to Evaluate efficacy and safety of erenumab in migraine prevention. These data showed the ARISE study met the primary endpoint. September 28, 2016